First defense for Zemiglo on 1st next month
A conflict for the sales right of the LG Life Sciences’ domestic antidiabetic ‘Zemiglo’ will be handled in a courtroom.
According to the industry on the 17th, Sanofi-Aventis Korea, the previous seller of Zemiglo, will start to process a damage suit against LG Life Sciences, the original develop...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
